Morgan Stanley continues to recommend Allergan Inc. AGN with a PT of $85.
“Many investors wonder about what is in Allergan Inc.'s pipeline, so we conducted a deep dive analysis on clinical trial websites to try to uncover public information to facilitate analysis,” Morgan Stanley writes.
“We were pleased to find that the number of key late stage pipeline readouts (six) over the next nine months matches #s of some major pharma.”
Allergan closed Friday at $74.77.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in